State Street® SPDR® S&P® Biotech ETF holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
State Street® SPDR® S&P® Biotech ETF XBI
Morningstar’s Analysis XBI
Will XBI outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 13.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Apogee Therapeutics Inc | 1.61 | 160M | Healthcare |
Oruka Therapeutics Inc | 1.42 | 141M | Healthcare |
Kymera Therapeutics Inc Ordinary Shares | 1.41 | 140M | Healthcare |
Erasca Inc | 1.39 | 139M | Healthcare |
Dianthus Therapeutics Inc | 1.31 | 130M | Healthcare |
Viking Therapeutics Inc | 1.30 | 129M | Healthcare |
Spyre Therapeutics Inc | 1.28 | 128M | Healthcare |
Moderna Inc | 1.28 | 128M | Healthcare |
Twist Bioscience Corp | 1.28 | 127M | Healthcare |
CG Oncology Inc | 1.27 | 126M | Healthcare |